APR OD031
Alternative Names: Amino acid extended release - APR Applied Pharma Research; APR-OD031Latest Information Update: 23 Feb 2025
Price :
$50 *
At a glance
- Originator APR Applied Pharma Research
- Class Amino acids
- Mechanism of Action Phenylalanine hydroxylase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Phenylketonuria
Most Recent Events
- 11 Feb 2025 Preclinical development of APR OD031 in Phenylketonuria is still ongoing in Switzerland (PO) (APR Applied Pharma Research pipeline, February 2025)
- 28 Apr 2024 No recent reports of development identified for preclinical development in Phenylketonuria in Switzerland (PO)
- 13 Apr 2020 APR OD031 is available for licensing as of 13 Apr 2020. https://www.apr.ch/applied-pharma-research/healthcare-partners/